FDAapproval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Nephrology · Complement Inhibition
- Sub-indication
- General
Related signal: Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment